anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a solid bathing agent containing peroxocarbonate, an organic acid and a hydrogen carbonate, excellent in blood circulation-improving effect, sterilizing effect and organic substance-decomposing effect and capable of dissolving in throwing in warm bath and reacting with water to generate oxygen. CONSTITUTION:This bathing agent is obtained by adding an organic acid (e.g. succinic acid) in an amount equivalent to neutralize a peroxocarbonate to the peroxocarbonate (e.g. sodium peroxocarbonate) at a molar ratio of 4:6 to 6:4 and further adding hydrogencarbonate (e.g. sodium hydrogencarbonate) in an amount of 0.5-2wt.%, preferably 1wt.% based on total amount of these both component to these both components, mixing these components, molding the mixture under pressure by a hydraulic molding machine and solidifying the mixture. The bathing agent is readily soluble in water, free from unpleasant odor an irritation to skin and does not leave harmful substances on the skin. Since oxygen generated by contact with water has sterilizing effect and cleansing effect, the organic substance can be decomposed and removed and stain or sliminess of the bathing tank and bathing kettle can be removed. Further, since foam-like oxygen gas can be generated, blood circulation-improving effect similar to that of carbonic acid spring is also obtained.
A central station is provided to which the pharmacy can forward calls at the convenience of the pharmacy. A caller will call in to the pharmacy to request a refill and the call will be automatically routed to the central facility unbeknownst to the caller. The central station will obtain the refill information required, preferably by means of an automated computer system as is known in the art. This information can then be transferred to the pharmacist in a number of ways, such as by periodically faxing the information to the pharmacy. Voice messages could be flagged and the pharmacist would have to call into the central facility to obtain the voice mail message. Alternatively, a PC could be installed in the pharmacy having a reduced version of a complete, stand-alone program. The refill information can then be sent to the pharmacy by modem and the pharmacist could see a computer display of the refill orders and could hear voice messages. Alternatively, the information could be e-mailed to the pharmacy. Finally, a pager system may be utilized to alert the pharmacist to retrieve orders by telephone with a password. It should also be noted that orders could be taken by the central station over the Internet rather than merely through customer calls. The central station can communicate with a pharmacy management service to obtain prescription refill authorization.
This study was performed at The Stress Rehabilitation Clinic at the University hospital of Umeå. In total 161 patients with diagnosed exhaustion disorder were recruited consecutively to the study from March 2010 until June 2013. Participants were all in age span 18-60 years old, had an ongoing employment and were assessed as suitable for a 24-week multimodal rehabilitation, which consisted of cognitive behavioural therapy in group (maximum eight persons), prescription of physical activity/exercise (FaR©) and vocational measures with rehabilitation meetings. A randomization by group was performed after 12 weeks of multimodal rehabilitation to one of three conditions; A/ continued multimodal rehabilitation, B/ addition of a computer-based cognitive training, and C/ addition of physical fitness training. The added training was performed during the last 12 weeks of rehabilitation (week 12 to 24) and with three weekly training occasions. Primary endpoint was change in cognitive functioning, estimated as a global brain score. Secondary endpoints were changes in different specific neuropsychological tasks, estimated psychological wellbeing, physical capacity, work ability, health-related quality of life and cost-effectiveness. A long-term follow-up was performed one year after termination of the interventions (at week 76).
Silymarin has ameliorated obesity, type 2 diabetes (T2DM), and insulin resistance (IR) in combination with standard therapy, diet, or exercise in recent studies. Obesity and IR are the main risk factors for developing T2DM and other metabolic disorders. Today, there is a need for new strategies to target IR in patients with these metabolic diseases. In the present longitudinal study, a group of non-diabetic insulin-resistant women with type 1 and type 2 obesity were given silymarin for 12 weeks, with no change in habitual diet and physical activity. We used the Homeostatic Model Assessment for Insulin Resistance Index (HOMA-IR) to determine IR at baseline and after silymarin treatment (t = 12 weeks). We obtained five timepoint oral glucose tolerance tests, and other biochemical and clinical parameters were analyzed before and after treatment. Treatment with silymarin alone significantly reduced mean fasting plasma glucose (FPG) and HOMA-IR levels at 12 weeks compared to baseline values (p < 0.05). Mean fasting plasma insulin (FPI), total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (Tg), indirect bilirubin, and C-reactive protein (CRP) levels decreased compared to baseline values, although changes were non-significant. The overall results suggest that silymarin may offer a therapeutic alternative to improve IR in non-diabetic individuals with obesity. Further clinical trials are needed in this type of patient to strengthen the results of this study.
Methoxsalen Soft Gelatin Capsules USP contains 10mg methoxsalen. Methoxsalen occurs as white to pale yellow crystals and can be obtained naturally from seeds of Ammi majus and roots of Heracleum Candicans or through synthesis. Methoxsalen is practically insoluble in water, freely soluble in chloroform, soluble in boiling alcohol, in acetone, in acetic acid, in propylene glycol, and in benzene, sparingly soluble in boiling water and in ether. The chemical name of methoxsalen is 9-methoxy-7H-furo [3,2-g] [1] benzopyran-7-one; its empirical formula is C12H8O4 and the molecular weight is 216.19. The structural formula is:

Methoxsalen Capsules are available as soft gelatin capsules containing the following inactive ingredients: Citric acid anhydrous, D & C yellow 10, FD & C blue 1, Gelatin, Glycine, Glycerin, Isopropyl alcohol, Medium chain triglyceride, Polyethylene glycol 400, Polysorbate 80, Purified water, Titanium dioxide and Opacode black.

The opacode black contains Propylene glycol, Shellac glaze (Modified) IN SD-45, N-Butyl alcohol, Black iron oxide, Isopropyl alcohol and Ammonium hydroxide.
FIELD: chemistry. ^ SUBSTANCE: invention relates to compounds of formula I and their pharmaceutically acceptable salts. The disclosed compounds have CDK1 and/or CDK2 kinase inhibiting activity. In formula R1 is selected from hydrogen, hydroxy-lower alkyl, C3-C6 cycloalkyl and R2-(X)n; X is selected from lower alkylene, hydroxy-lower alkylene, lower cycloalkylene or lower alkanoyloxy-lower alkylene; R2 is and is selected from phenyl and a 5- or 6-member heteroaromatic ring containing 1 or 2 heteroatoms selected from a group consisting of sulphur and nitrogen; R5 and R6 are independently selected from a group consisting of hydrogen, lower alkyl, halogen and lower alkoxy; and n equals 0 or 1. ^ EFFECT: design of a pharmaceutical composition for treating and preventing diseases whose condition can be improved by inhibiting CDK1 and/or CDK2 kinase, containing an effective amount of formula I compounds. ^ 47 cl, 19 ex
The present invention relates to a system and a method for providing drug information using a block chain. A manufacturer / importer PC, a wholesaler PC, a pharmacy / hospital PC, and a disposal company PC are in connection with a server of the Ministry of Food and Drug Safety through an internet network or a dedicated line. Quantities of drugs and psychotropic drugs according to manufacture, import, supply, return, and disposal are confirmed. Also, data with respect to consumer information, quantities, supplied times, etc. according to the providing of the drugs and psychotropic drugs from pharmacies / hospitals to the consumers is reported through the pharmacy / hospital PC in real time or in a periodic manner. Accordingly, illegal distribution of the drugs and psychotropic drugs can be prevented, and artificial extraction and illegal use of the same by the consumers can be prevented at the same time.
FIELD: medicine. SUBSTANCE: composition has the following components, %: aralia roots 8-12; schizandra seeds 8-12; nettle leaves 13-17; mountain ash fruits 3-7; viburnum fruits 3-7; wild rose fruits 3-7, and Eleutherococcus senticosus roots - the rest. Composition can be used for organism resistance increase to oxygen decreased content (to enhance resistance to hypoxia), prophylaxis of intoxication with agents inducing formation of methemoglobin and as tonic agent. Preparation can be used also for prophylaxis and correction of functional disorders and sicknesses caused by effect of stress and environment factors, different radiation forms and so on. EFFECT: enhanced effectiveness of composition. 2 cl
Primary hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. At present, surgery is the first choice and the most effective way to treat it. Based on the case review, the investigators found that the recovery rate of perioperative liver function was correlated with survival. Therefore, it is of great clinical significance to improve the recovery rate of postoperative liver function. Gut microbiota participate in many physiological activities of human body, such as metabolic regulation, immune homeostasis and hormone regulation. However, gut microbiota imbalance, excessive growth of pathogenic microorganisms and changes in intestinal mucosal permeability lead to intestinal bacterial ectopia and bacterial metabolites entering the liver through enterohepatic circulation. The continuous inflammatory stimulation aggravate the progress of liver disease. Therefore, it is helpful to explore the influence of gut microbiota on postoperative liver function recovery and find out the different microbiota, in order to improve the postoperative liver function recovery rate, shorten the perioperative hospital stay and prolong the survival of patients.

According to the recovery level of liver function on the fifth day after the operation, liver resection patients on HCC were divided into the recovery group and the recovery delay group which comparing on the time point of before the surgery and five days after the surgery. The patients on benign liver disease were used as a control. The investigators attempt to identify the differential microbiota and validate this finding in a mouse hepatectomy model.
There are described imaging agents and methods of use in the imaging of Factor XIIla. Also described is the use of imaging agents and methods in detecting transglutaminase and/or Factor Xllla activity. The imaging agents have a peptide or a pseudopeptide moiety that is a substrate for one or more transglutaminase, and a detectable moiety that is detectable in NIR, optical and/or PET imaging. The imaging agents may have use in imaging, diagnosis, surgery, treatment or therapy monitoring. For example, the imaging agents may have use in the diagnosis, surgery, treatment or monitoring therapy of rheumatoid arthritis, atherosclerosis, fibrosis or cancer. Also, the imaging agents may have use in the diagnosis, surgery or treatment of sites of thrombosis, embolism or inflammation.
An analgesic tablet comprises at least two juxtaposed layers, one being sodium salicylate and another comprising acetylsalicylic acid and substantial portion of which is associated with a release retardant, said salicylate and acid being present in a ration of between 1 : 1.4 and 1 : 7 by weight.  The layers need p  not be flat. A non-retarded portion of acetylsalicylic acid may be mixed with the retarded portion in one layer or it may form a separate layer of the tablet.  Specified retardants are shellac acetate-crotonic acid copolymers, cellulose acetate phthalate, vinyl acetate-maleic anhydride copolymers, polymethacrylic acid, copolymers of ethylene and maleic anhydride, hydrogenated castor oil, hydrogenated soybean oil, glyceryl monostearate, diglycol stearate, cetyl and stearyl alcohols, palmitric and linoleic acids, beeswax, carnauba wax, and thickeness e.g. bentonite, methylcellulose, acacia.  The release retardant need not form a coating on the acetylsalicylic acid particles.  The tablets may include lubricants e.g. talc, Mg stearate, stearic acid; disintegrators e.g. starch, lactose, Na carboxymethyl cellulose; resins e.g. ion-exchange resins; binders e.g. gelatin, acacia, polyvinylpyrrolidone, sugar syrup; dyes, fillers, pigments, flavouring agents, and odorants.
Obstructive sleep apnea is an exceedingly common disease with major neurocognitive and cardiovascular consequences. The current primary treatment e.g. Continuous positive airway pressure (CPAP) is effective but poorly tolerated by many patients particularly those with mild-moderate disease. Secondary treatments such as oral appliances to advance the mandible or surgical procedures to enlarge the airway are commonly appealing to the patient. However, these approaches have only modest success in reducing apnea frequency to an acceptable level. Thus, finding tolerable and effective therapy for sleep apnea remains an important objective.

The causes of sleep apnea vary between patients. Targeted therapy according to the underlying causes of sleep apnea in individual patients is likely to be most effective. However, current therapeutic options for sleep apnea are quite limited. The purpose of this physiological research study is to determine if taking eszopiclone (Lunesta)changes the breathing effort required to briefly wake people with obstructive sleep apnea from sleep (the arousal threshold) and if administration of the sedative medication eszopiclone (Lunesta) to certain sleep apnea patients (those with a low arousal threshold ie wake up easily) would be beneficial.
CVD includes diseases that affect the heart and blood vessels. The underlying cause of CVD is atherosclerosis, in which fatty plaques develop on the inner walls of arteries. There are many risk factors for CVD, including inflammation, high blood pressure, high cholesterol, and obesity. Research has shown that CVD mortality rates differ greatly between Chinese immigrants living in NYC and individuals living in China. Because of this difference, it is important to understand the impact of immigration and acculturation on health habits and psychosocial factors, which may influence the development of CVD. This study will gather information from Chinese immigrants in NYC to identify the impact of immigration and acculturation on behavior and CVD risk factors. In addition, results from this study may provide insight into the CVD risk patterns in other immigrant groups.

This study will enroll Chinese immigrants living in NYC. Participants will attend one study visit and will complete questionnaires to assess their health habits (diet, physical activity, and smoking), stress levels, and socioeconomic status. Participants will also undergo a physical examination and blood collection.
BACKGROUND: Cardiac fibroblast activation contributes to adverse remodeling, fibrosis, and dysfunction in the pressure-overloaded heart. Although early fibroblast TGF-β (transforming growth factor-β)/Smad (small mother against decapentaplegic)-3 activation protects the pressure-overloaded heart by preserving the matrix, sustained TGF-β activation is deleterious, accentuating fibrosis and dysfunction. Thus, endogenous mechanisms that negatively regulate the TGF-β response in fibroblasts may be required to protect from progressive fibrosis and adverse remodeling. We hypothesized that Smad7, an inhibitory Smad that restrains TGF-β signaling, may be induced in the pressure-overloaded myocardium and may regulate fibrosis, remodeling, and dysfunction.
METHODS: The effects of myofibroblast-specific Smad7 loss were studied in a mouse model of transverse aortic constriction, using echocardiography, histological analysis, and molecular analysis. Proteomic studies in S7KO (Smad7 knockout) and overexpressing cells were used to identify fibroblast-derived mediators modulated by Smad7. In vitro experiments using cultured cardiac fibroblasts, fibroblasts populating collagen lattices, and isolated macrophages were used to dissect the molecular signals responsible for the effects of Smad7.
RESULTS: Following pressure overload, Smad7 was upregulated in cardiac myofibroblasts. TGF-β and angiotensin II stimulated fibroblast Smad7 upregulation via Smad3, whereas GDF15 (growth differentiation factor 15) induced Smad7 through GFRAL (glial cell line-derived neurotrophic factor family receptor α-like). MFS7KO (myofibroblast-specific S7KO) mice had increased mortality, accentuated systolic dysfunction and dilative remodeling, and accelerated diastolic dysfunction in response to transverse aortic constriction. Increased dysfunction in MFS7KO hearts was associated with accentuated fibrosis and increased MMP (matrix metalloproteinase)-2 activity and collagen denaturation. Secretomic analysis showed that Smad7 loss accentuates secretion of structural collagens and matricellular proteins and markedly increases MMP2 secretion. In contrast, Smad7 overexpression reduced MMP2 levels. In fibroblasts populating collagen lattices, the effects of Smad7 on fibroblast-induced collagen denaturation and pad contraction were partly mediated via MMP2 downregulation. Surprisingly, MFS7KO mice also exhibited significant macrophage expansion caused by paracrine actions of Smad7 null fibroblasts that stimulate macrophage proliferation and fibrogenic activation. Macrophage activation involved the combined effects of the fibroblast-derived matricellular proteins CD5L (CD5 antigen-like), SPARC (secreted protein acidic and rich in cysteine), CTGF (connective tissue growth factor), ECM1 (extracellular matrix protein 1), and TGFBI (TGFB induced).
CONCLUSIONS: The antifibrotic effects of Smad7 in the pressure-overloaded heart protect from dysfunction and involve not only reduction in collagen deposition but also suppression of MMP2-mediated matrix denaturation and paracrine effects that suppress macrophage activation through inhibition of matricellular proteins.
Residual normal plasma cells (NPCs), which compete with tumor plasma cells, play an important role in multiple myeloma. However, large-scale cohort studies investigating residual NPCs, especially at the minimal residual disease (MRD) phase, are currently lacking. In this study, we conducted a comprehensive investigation into the clinical significance of residual NPCs throughout the entire disease course in 1363 myeloma patients from the NICHE cohort (NCT04645199). Our results revealed that myeloma patients with high baseline NPCs ratio (≥5%) exhibited distinct indolent features, characterized by lower tumor burden, reduced frequencies of cytopenia, immunoparesis, and high-risk cytogenetics. Importantly, high residual NPCs ratio at diagnosis or relapse was independently associated with favorable survival. High absolute percentages of NPCs at undetectable MRD were related with superior clinical benefit and immune reconstitution. At MRD-positive phases, grouping based on NPCs ratio (<50%, 50-90%, ≥90%) demonstrated better risk stratification compared to residual tumor log levels. Based on the time-dependent NPCs ratio trend, we developed a dynamic MRD model that classifies patients into three groups with diverse longitudinal trends, leading to distinct prognoses. Collectively, residual NPCs serves not only as a valuable complementary biomarker for risk stratification but also provides valuable insights on reclassifications and kinetics of MRD.
To improve the accuracy of radical resection by reducing the risk of missed diagnosis of positive margin, this study will explore clinical application of near-infrared fluorescence imaging with modified low-dose SWIG technique in guiding radical resection of malignant soft tissue tumor. The investigators conduct a multi-center, multi-subgroup, prospective randomized controlled trial. The participants will be first stratified according to histological type involving dermatofibrosarcoma protuberans (DFSP) and skin squamous cell carcinoma (sSCC). The patients with DFSP or sSCC will be then randomly assigned to three groups. Patients in the control group will not receive ICG administration. The ICG was injected intravenously 24 hours before surgery, at a dose of 0.25 mg/kg in the first experimental group and 25 mg/patient in the second experimental group, respectively. The patients in the control groups will undergo traditional assessment of surgical margins.The patients in the experimental groups, on the other hand, will be scheduled to intraoperative near-infrared fluorescence imaging to scan gross tumor, tumor bed and cross-sectional specimen. The 2-year local recurrence rate will be regarded as primary outcome. The number of positive margins will be compared among groups. The investigators will also calculate the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) with 95% confidence intervals based on fluorescent signal of tumor bed in the experimental groups.
PURPOSE:To provide a preventive and remedy for the diseases caused by the immunoinsufficiency of man and animal, especially effective to increase the resistance to the infectious diseases of man and animal, and having low toxicity and high stability, by using a polyprenyl alcohol compound as an active component. CONSTITUTION:The polyprenyl alcohol compound of formula I (a and b are H or together form a bond; n is integer of 1-10) is used as an active component. A concrete example of the compound of formula is 3,7,11,15,19,23,27,31-octamethyl- 2,6,10,14,18,22,26,30-dotriacontaoctaen-1-ol. It can be prepared via several steps using the compound of formula II and a cyanoacetic acid lower alkyl ester as starting raw materials. It can be administered in the form of e.g. granules, powder, etc., and can be prepared by a conventional process using a conventional carrier.
This study will build upon a previous finding that showed a triglyceride lowering effect of prescription omega-3 in combined therapy with statins. The proposed study will use a simple change from baseline design on 15 subjects who are hypertriglyceridemic on stable statin therapy. The protocol involves 3 study visits; each involve drawing a blood sample: day 1 - screening (blood draw for qualification and safety); day 7 - before taking prescription omega-3 fatty acids (Lovaza, 4 capsules/d; GlaxoSmithKline), day 63 -after taking prescription omega-3 fatty acids (Lovaza, 4 capsules/d; GlaxoSmithKline). The proposed study will include up to 15 subjects and will utilize several different measures of lipoprotein structure and function. The investigators will measure functional parameters such as the binding affinity of lipoproteins before and after treatment with omega-3 fatty acids. The investigators will also measure fatty acid, oxylipin and apolipoprotein content of plasma, very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL) and high-density lipoprotein (HDL).
An object of the present invention is to provide a novel agent for inhibiting proliferation of SARS-CoV-2 and a novel agent for preventing onset of COVID-19. According to the present invention, there is provided an agent for inhibiting proliferation of SARS-CoV-2 comprising a lactic acid bacterium as an active ingredient. Also, according to the present invention, there is provided an agent for preventing onset of COVID-19 comprising a lactic acid bacterium as an active ingredient. The lactic acid bacterium which is the active ingredient of the present invention is preferably  Lactococcus lactis  subsp.  lactis.  The agent of the present invention is preferably in the form of a food composition.